Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
8 hedge funds and large institutions have $76K invested in Altamira Therapeutics Ltd in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
14% more funds holding
Funds holding: 7 → 8 (+1)
68% less capital invested
Capital invested by funds: $241K → $76K (-$165K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$35.8K |
| 2 |
CGA
Crescent Grove Advisors
Lake Forest,
Illinois
|
+$15.3K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$10.2K |
| 4 |
Barclays
London,
United Kingdom
|
+$5.11K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$164K |
| 2 |
VF
Virtu Financial
New York
|
-$61.3K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$54K |
| 4 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
-$28K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$20.4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $26K | +$35.8K | +7 | New |
|
|
2
Citadel Advisors
Miami,
Florida
| $11K | -$20.4K | -4 | -57% |
|
|
CGA
3
Crescent Grove Advisors
Lake Forest,
Illinois
| $9K | +$15.3K | +3 | New |
|
|
VF
4
Virtu Financial
New York
| $8K | -$61.3K | -12 | -86% |
|
5
Geode Capital Management
Boston,
Massachusetts
| $8K | – | – | – |
|
|
TSS
6
Two Sigma Securities
New York
| $6K | +$10.2K | +2 | New |
|
|
7
Barclays
London,
United Kingdom
| $5K | +$5.11K | +1 | New |
|
|
8
UBS Group
Zurich,
Switzerland
| $3K | +$5.11K | +1 | New |
|
|
9
Morgan Stanley
New York
| – | -$164K | -32 | Closed |
|
|
WS
10
Wedbush Securities
Los Angeles,
California
| – | -$54K | -19 | Closed |
|
|
CLOS
11
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| – | -$28K | -10 | Closed |
|
CYTO Hedge Fund Activity: Q4 2018 in Review
8 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q4 2018, worth a combined $76K — down 68% from $241K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CYTO positions and 4 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $35.8K. The largest seller was Morgan Stanley, exiting entirely with an estimated $164K sold.
- 8 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q4 2018, up from 7 in Q3 2018.
- Funds reported $76K of Altamira Therapeutics Ltd stock for Q4 2018, down 68% quarter-over-quarter.
- 5 funds opened new Altamira Therapeutics Ltd positions in Q4 2018 and 4 closed out, a net change of +1 holder.
- The largest Altamira Therapeutics Ltd buyer in Q4 2018 was Susquehanna International Group, an estimated $35.8K added.
- The largest Altamira Therapeutics Ltd seller in Q4 2018 was Morgan Stanley, an estimated $164K sold.
Based on aggregated 13F filings for Q4 2018.